Three Year Outcomes of Combined Hydrus Microstent With iTrack Canaloplasty
NCT ID: NCT07073937
Last Updated: 2026-01-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ENROLLING_BY_INVITATION
100 participants
OBSERVATIONAL
2025-08-01
2026-11-04
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Effectiveness of the Hydrus Microstent
NCT05198297
Efficacy of Surgical Systems in Combination With Phacoemulsification: a Retrospective Analysis
NCT06953349
Hydrus Microstent for Refractory Open-Angle Glaucoma
NCT03267134
Multicenter Glaucoma Study Investigating Standalone Canaloplasty
NCT05786196
MIGS VS SLT Comparison in Glaucoma Patients
NCT02512133
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Glaucoma patients
Patients from the Moran Eye Center who have open-angle glaucoma and have had a combination of Hydrus and 360-degree canaloplasty with concomitant cataract surgery, who have at least three years of follow-up data.
Retrospective chart review
Retrospective study; a total of approximately 100 subjects have been identified to have had minimum 36 months follow-up.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Retrospective chart review
Retrospective study; a total of approximately 100 subjects have been identified to have had minimum 36 months follow-up.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Mild: Definite optic disc, RNFL, or macular imaging abnormalities consistent with glaucoma and a normal visual field as tested with standard automated perimetry (SAP)
* Moderate: Definite optic disc, RNFL, or macular imaging abnormalities consistent with glaucoma, and visual field abnormalities in one hemifield that are not within 5 degrees of fixation as tested with SAP
* Severe: Definite optic disc, RNFL, or macular imaging abnormalities consistent with glaucoma, and visual field abnormalities in both hemifields and/or loss within 5 degrees of fixation in at least one hemifield as tested with standard automated perimetry (SAP)
* Patients who have had prior selective laser trabeculoplasty (SLT) are allowed
Exclusion Criteria
* Prior retinal surgery
* Prior MIGS or incisional glaucoma surgery
* Angle closure glaucoma and other secondary glaucoma
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Alcon Research
INDUSTRY
University of Utah
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Craig Chaya
Assistant Professor (Clinical)
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Craig Chaya, MD
Role: PRINCIPAL_INVESTIGATOR
University of Utah John A. Moran Eye Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Utah John A. Moran Eye Center
Salt Lake City, Utah, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
186645
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.